Abstract
PURPOSE: The ATTAIN program compared telavancin (TLV), an investigational lipoglycopeptide antibiotic, with vancomycin (VAN) for treatment of hospital-acquired pneumonia (HAP) due to Gram-positive pathogens including MRSA. This subgroup analysis examined the baseline characteristics and clinical outcomes in bacteremic HAP cases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
